Posted by Michael Wonder on 28 Aug 2017
Restricted drug treatments for people with MS justified
28 August 2017 - New research justifies increased access to restricted drug treatments for people with multiple sclerosis.
The Multiple Sclerosis Society of New Zealand has met with senior executives of PHARMAC requesting a review of the current criteria for access to drugs that help to reduce the effects of multiple sclerosis.
The current criteria were last reviewed in 2014. Since then, new research has shown that people with MS derive significant benefits from the drugs long after the disease has progressed beyond the scope of PHARMAC’s current Special Authority Criteria, when funding for the drugs ceases.
